Gilead Sciences

Gilead Sciences, a US-based Pharmaceutical Preparation Manufacturing company, has demonstrated its commitment to climate action through various initiatives and targets.

In 2024, Gilead Sciences reported Scope 1 emissions of approximately 53.86 million kg CO2e and Scope 2 (market-based) emissions of about 17.14 million kg CO2e. Their Scope 3 emissions for the same year were approximately 998.10 million kg CO2e, with significant contributors including purchased goods and services (about 731.44 million kg CO2e) and capital goods (approximately 42.71 million kg CO2e).

Looking back, in 2023, the company's Scope 1 emissions were approximately 564.35 million kg CO2e, and Scope 2 (market-based) emissions were around 226.03 million kg CO2e. Scope 3 emissions in 2023 were roughly 1.15 billion kg CO2e, with purchased goods and services being the largest category at about 865.32 million kg CO2e. In 2022, Scope 1 emissions were about 55.92 million kg CO2e, Scope 2 (market-based) emissions were approximately 26.29 million kg CO2e, and Scope 3 emissions totalled around 1.20 billion kg CO2e, including about 858.10 million kg CO2e from purchased goods and services.

Gilead Sciences has set ambitious reduction targets. The company aims to reduce its Scope 1 and 2 greenhouse gas (GHG) emissions by 25% by 2025, using a 2016 baseline. Furthermore, Gilead Sciences is committed to achieving a 46% reduction in absolute Scope 1 and 2 GHG emissions by 2030, based on a 2019 baseline. This target is validated by the Science Based Targets initiative (SBTi) and is consistent with reductions required to keep global warming to 1.5°C. The company also aims to reduce absolute Scope 3 GHG emissions by 15% over the same timeframe (2019 baseline to 2030). Gilead Sciences has also publicly declared a net-zero operations ambition for Scope 1 and 2 GHG emissions by 2030.